High-dose PPI changes ‘effective’: PBAC

Decrease in esomeprazole and increase in pantoprazole scripts likely due to restriction changes, says PBAC, though full picture obscured by lack of OTC and private data Restriction changes established in 2019 have been successful at reducing use of high-dose PPIs by moving patients to lower-dose PPIs, the PBAC said in response to data recently provided